Please assess the completion status of the following clinical trial:

Trial Title: Fibroblast Growth Factor-23 (FGF23) Reduction in Predialysis Chronic Kidney Disease (CKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* We will include stage 3a, 3b and 4 CKD patients, aged 18 years or over with normal serum phosphate levels (≤ 4.6 mg/dl)~Exclusion Criteria:~* Patients with rapidly advancing renal failure who thus might develop hyperphosphatemia or end stage renal disease requiring initiation of dialysis during the study period~* Patients expected to require dialysis initiation within the follow up period~* Patients with hyperphosphatemia \> 4.6 mg/dl~* Patients with any previous or current treatment with phosphate binders or active vitamin D (doxercalciferol or calcitriol)~* Malnutrition, defined as a serum albumin \< 3.0 mg/dl~* Patients with liver disease (ALT or AST \> 100 U/L) or cholestasis (direct bilirubin \> 1.0 mg/dl) because this can limit their ability to absorb fat soluble vitamins such as vitamin D~* Anemia, defined as a hematocrit \< 27% at the screening visit~* Medical conditions impacting Pi metabolism-primary hyper- or hypoparathyroidism; Patients with previous subtotal parathyroidectomy; gastrointestinal malabsorption disorders such as Crohn's Disease, ulcerative colitis, celiac disease, or severe liver dysfunction;~* Patients with outpatient counseling by a renal nutritionist within the previous 6 months~* Hospitalization within the previous 4 weeks~* Pregnancy or breastfeeding mothers~* Patients unable to independently provide written informed consent - prisoners, mentally incompetent, minors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 900 mg Phosphate Diet-LC (Type: ACTIVE_COMPARATOR): dietary phosphorus restriction (900 mg/day of phosphorus) + phosphorus binder (Lanthanum Carbonate)
- Ad Libitum Diet-LC (Type: ACTIVE_COMPARATOR): no dietary intervention + phosphorus binder (Lanthanum Carbonate)
- 900 mg Phosphate Diet-LC Placebo (Type: ACTIVE_COMPARATOR): dietary phosphorus restriction (900 mg/day of phosphorus) + placebo
- Ad Libitum Diet-LC Placebo (Type: PLACEBO_COMPARATOR): no dietary intervention + placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).